| Inflammation |
| Completed | 3 | 915 | Europe, Canada, RoW | SQ tree SLIT-tablet, Placebo | ALK-Abelló A/S, Parexel | Allergy | 07/23 | 07/23 | | |
2021-001447-27: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis |
|
|
| Not yet recruiting | 3 | 45 | Europe | ANB019, Solution for infusion | AnaptysBio Inc., AnaptysBio Inc. | Subjects with generalized pustular psoriasis, GPP is a severe,debilitating,and life-threatening systemic inflammatory disease.Skin lesions manifest with widespread sterile pustules on erythematous skin covering almost the entire body., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT05540717: Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen |
|
|
| Completed | 3 | 858 | Europe, US, RoW | PQ Grass, Placebo | Allergy Therapeutics | Seasonal Allergic Rhinitis, Rhinoconjunctivitis | 11/23 | 11/23 | | |
2021-003665-35: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection |
|
|
| Not yet recruiting | 3 | 150 | Europe, RoW | Pegylated Interferon Lambda-1a, 361529, Solution for injection/infusion in pre-filled syringe | Eiger BioPharmaceuticals, Inc., EIGER BIOPHARMACEUTICALS, INC., Eiger BioPharmaceuticals, Inc. | Chronic Hepatitis Delta Virus (HDV) Infection, Chronic Hepatitis Delta Virus (HDV) Infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04874714: Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis |
|
|
| Terminated | 3 | 18 | Europe | MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000), Placebo subcutaneous | Inmunotek S.L., BioClever 2005 S.L., NTS hub S.L | Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy | 10/23 | 10/23 | | |
NCT04891237: Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen |
|
|
| Recruiting | 3 | 180 | Europe | 10,000 MG01 + 10,000 T517, Grasses and olea 10,000, 30,000 MG01 + 10,000 T517, Grasses and olea, Placebo | Inmunotek S.L. | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 10/25 | 01/26 | | |
2022-002389-33: Prevention of Recurrence post Operatively with Guselkumab Relative to Endoscopy and Symptoms Prevenzione delle recidive post operatorie con guselkumab in relazione all'endoscopia e ai sintomi |
|
|
| Not yet recruiting | 3 | 370 | Europe | Guselkumab, [CNTO1959], Solution for injection | JANSSEN CILAG INTERNATIONAL NV, Janssen-Cilag International NV, Janssen Research & Development | Crohn's Disease After Surgical Resection Malattia di Crohn dopo resezione chirurgica, Inflammatory bowel disease (IBD) Malattia infiammatoria dell'intestino, Diseases [C] - Immune System Diseases [C20] | | | | |
FEXPRESAR, NCT05692154: A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis |
|
|
| Completed | 3 | 95 | Canada | Fexofenadine, Placebo | Opella Healthcare Group SAS, a Sanofi Company | Seasonal Allergic Rhinitis | 03/23 | 03/23 | | |
| Recruiting | 3 | 70 | Europe | Belimumab Injection, Benlysta subcutaneous injection of 200mg | Leiden University Medical Center, Dutch Kidney Foundation, GlaxoSmithKline | Lupus Erythematosus, Systemic | 12/23 | 09/25 | | |
NCT04898283: Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. |
|
|
| Recruiting | 3 | 180 | Europe | 10,000 MG01 +10,000 T521, 30,000 MG01 +10,000 T521, Placebo subcutaneous | Inmunotek S.L. | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 12/23 | 04/24 | | |
OPTIMIZE-2, NCT06128369: Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery |
|
|
| Recruiting | 3 | 160 | US | Dexamethasone Ophthalmic Suspension, OCS-01, Vehicle of OCS-01 | Oculis, ORA, Inc. | Inflammation Eye, Pain, Postoperative, Cataract | 07/24 | 12/24 | | |
GO-GUT, NCT03270501: Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation |
|
|
| Completed | 3 | 64 | Europe | Golimumab, ileocoloscopy | University Ghent, Merck Sharp & Dohme LLC, the Flanders Institute for Biotechnology | Axial Spondyloarthritis | 12/23 | 12/23 | | |
NCT04846491: A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B |
|
|
| Completed | 3 | 475 | RoW | Peginterferon alfa-2b injection, TDF | Xiamen Amoytop Biotech Co., Ltd., Peking University First Hospital | Chronic Hepatitis B | 11/23 | 12/23 | | |
| Recruiting | 3 | 150 | Europe | 10,000 MM09, 30,000 MM09, Placebo subcutaneous | Inmunotek S.L., BioClever 2005 S.L. | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 01/24 | 12/25 | | |
| Recruiting | 3 | 158 | Europe | Infliximab subcutaneous, Remsima 120mg solution s.c., Immunosuppressive Agents, 6-mercaptopurine 1-1.5 mg/kg oral, or, if already on oral azathioprine or thioguanine continuous dosing 2-2.5mg/kg, or 20mg once daily respectively, In case of adverse events or investigator's individual consideration, instead of thiopurine, methotrexate 15 mg/week s.c. (or oral) in combination with oral folic acid 5 mg/week | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celltrion | Inflammatory Disease, Disease Crohn, Bowel Disease | 01/24 | 07/24 | | |
| Recruiting | 3 | 350 | Europe | House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae, Placebo | Probelte Pharma S.L.U. | House Dust Mite Allergy | 02/24 | 02/24 | | |
NCT05970783: A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease |
|
|
| Recruiting | 3 | 414 | RoW | Jincaopian Tablets, ZY5301, Placebo | Beijing Konruns Pharmaceutical Co., Ltd. | Chronic Pelvic Pain | 02/24 | 11/24 | | |
PASSPORT, NCT06274294: Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC |
|
|
| Not yet recruiting | 3 | 130 | NA | CT-P13 | CMC Ambroise Paré, Paris IBD Center, Celltrion HealthCare France | Inflammatory Bowel Diseases | 01/25 | 01/25 | | |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated With Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 03/24 | 06/24 | | |
| Active, not recruiting | 3 | 135 | Europe, Canada, Japan, US, RoW | Inebilizumab, Placebo | Amgen | IgG4 Related Disease | 04/24 | 10/28 | | |
ATHENA, NCT06200207: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation |
|
|
| Recruiting | 3 | 680 | Europe, Canada, US, RoW | Ziltivekimab, Placebo | Novo Nordisk A/S | Heart Failure, Systemic Inflammation | 05/26 | 08/26 | | |
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Active, not recruiting | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 08/24 | 08/24 | | |
| Recruiting | 3 | 450 | US | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Perennial Allergic Rhinitis (PAR) | 05/25 | 05/26 | | |
| Active, not recruiting | 3 | 935 | Europe, Canada, US, RoW | Dupilumab SAR231893, Dupixent, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo | Sanofi, Regeneron Pharmaceuticals | Chronic Obstructive Pulmonary Disease | 02/24 | 05/24 | | |
|
|
NCT06413121: Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV |
|
|
| Recruiting | 3 | 1557 | RoW | Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV, Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV | Serum Institute of India Pvt. Ltd. | Diptheria Immunization, Tetanus Immunization, Pertussis Immunization, Hepatitis B Immunization, Haemophilus Influenzae Type B Immunization, Polio Immunization | 08/25 | 05/26 | | |
NCT05891496 / 2022-003384-24: A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease |
|
|
| Active, not recruiting | 3 | 24 | Europe, Canada, US | Semaglutide, Placebo | Novo Nordisk A/S, Novo Nordisk A/S | Alzheimers Disease | 08/24 | 09/25 | | |
NCT05908032: Study of CM310 in Subjects With Allergic Rhinitis |
|
|
| Active, not recruiting | 3 | 108 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Allergic Rhinitis | 05/24 | 07/24 | | |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Active, not recruiting | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 07/24 | 07/24 | | |
LIMT-2, NCT05070364: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV |
|
|
| Active, not recruiting | 3 | 150 | Europe, US, RoW | Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 06/24 | 01/25 | | |
2024-000141-26: The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India. |
|
|
| Not yet recruiting | 3 | 200 | RoW | Abrocitinib, PF-04965842, Film-coated tablet, Cibinqo | Pfizer Inc., Pfizer Inc. | Moderate to severe atopic dermatitis, Atopic dermatitis is also known as atopic eczema. It is a type of inflammation of the skin that results in itchy, red, swollen, and cracked skin., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis |
|
|
| Not yet recruiting | 3 | 30 | Europe, RoW | Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy | Takeda | Pouchitis | 12/29 | 12/29 | | |
NCT05613127: To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs |
|
|
| Not yet recruiting | 3 | 106 | RoW | Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL, HAVRIX 720 Junior 0.5 mL | Boryung Biopharma Co., Ltd. | Hepatitis A, Hep A | 07/24 | 11/24 | | |
NCT05400811: Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis |
|
|
| Not yet recruiting | 3 | 400 | Europe | MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL), Placebo subcutaneous, Placebo sublingual | Inmunotek S.L., BioClever 2005 S.L., NTS hub S.L | House Dust Mite Allergy, Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma | 07/24 | 07/25 | | |
NCT06436781: Effect of Maolactin™ FMR on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population |
|
|
| Not yet recruiting | 3 | 40 | RoW | Maolactin, Maltodextrin | RDC Clinical Pty Ltd | Post Exercise Inflammation, Exercise Recovery, Muscle Fatigue, Muscle Pain | 04/25 | 07/25 | | |
NCT06444763: Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population |
|
|
| Not yet recruiting | 3 | 100 | RoW | Maolactin, Maltodextrin | RDC Clinical Pty Ltd | Chronic Inflammation, Mobility, Muscle Pain, Joint Pain | 04/25 | 07/25 | | |
TiNivo-2, NCT04987203: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 343 | Europe, Canada, US, RoW | Tivozanib, Nivolumab | AVEO Pharmaceuticals, Inc., Parexel, Bristol-Myers Squibb | Renal Cell Carcinoma | 08/24 | 08/25 | | |
CLOSE-3, NCT05724446: Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population |
|
|
| Recruiting | 3 | 60 | Europe | Clobetasol Propionate, SVT-15473, Prednisolone acetate ophthalmic suspension, 1% | Salvat | Cataracts Infantile | 08/24 | 08/24 | | |
DESPRED, NCT05214911: Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children |
|
|
| Not yet recruiting | 3 | 248 | RoW | Desloratadine , Prednisolone, Desloratadine | Eurofarma Laboratorios S.A. | Allergic Rhinitis | 05/25 | 07/25 | | |
NCT05684380: Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) |
|
|
| Not yet recruiting | 3 | 514 | NA | MAZ-101association, DYMISTA® | EMS | Allergic Rhinitis | 11/24 | 05/25 | | |
LOWR6, NCT05229991: Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection |
|
|
| Active, not recruiting | 3 | 30 | RoW | Lonafarnib, LNF, Ritonavir, Norvir | Soroka University Medical Center, Eiger BioPharmaceuticals | Hepatitis D, Chronic | 12/24 | 04/25 | | |
| Recruiting | 3 | 280 | Europe | Prednisolone, Losartan | Valentina Puentmann, Bayer, Alcedis GmbH | COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle, Remodeling, Vascular, Left Ventricular Dysfunction, Exercise Intolerance, Vascular Inflammation, Microvascular Angina | 12/24 | 12/28 | | |
SIERRA, NCT06272409: Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children. |
|
|
| Not yet recruiting | 3 | 318 | NA | DEP114, Desloratadine 0.5 MG/ML | EMS | Allergic Rhinitis | 03/25 | 04/27 | | |
ALERZIN, NCT05637710: Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil |
|
|
| Not yet recruiting | 3 | 754 | RoW | Administration of investigation of Eurofarma drug, Investigation drug, Administration of Comparator, Comparator drug | Eurofarma Laboratorios S.A. | Allergic Rhinitis | 04/26 | 08/26 | | |
CRYSTAL, NCT05668455: Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses) |
|
|
| Recruiting | 3 | 30 | Europe | Hydrocortisone, Dexamethasone, Povidone | Agnes, Direction Générale de l'Offre de Soins, Laboratoires Thea | Ocular Inflammation, Ocular Prostheses | 05/25 | 07/26 | | |
ZEUS, NCT05021835 / 2020-004853-59: - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation |
|
|
| Recruiting | 3 | 6200 | Europe, Canada, Japan, US, RoW | Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C) | Novo Nordisk A/S, Novo Nordisk A/S | Cardiovascular Risk, Chronic Kidney Disease, Inflammation | 09/25 | 01/26 | | |
| Active, not recruiting | 3 | 859 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
| Active, not recruiting | 3 | 941 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
| Recruiting | 3 | 200 | Europe, Canada, Japan, US, RoW | Obexelimab, Placebo | Zenas BioPharma (USA), LLC | IgG4 Related Disease | 10/25 | 12/26 | | |
| Active, not recruiting | 3 | 36 | Europe | Lenalidomide, Revlimid, Dexamethasone, No further treatment | University College, London, Cancer Research UK, Celgene | Plasmacytoma | 04/26 | 12/26 | | |
| Recruiting | 3 | 390 | Canada, US | Abatacept plus, Orencia, Placebo | Massachusetts General Hospital, Bristol-Myers Squibb | Myocarditis Acute, Cancer | 11/26 | 04/27 | | |
HERMES, NCT05636176: A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation |
|
|
| Recruiting | 3 | 5600 | Europe, Canada, Japan, US, RoW | Ziltivekimab, Placebo | Novo Nordisk A/S | Heart Failure | 07/27 | 07/27 | | |
SHINE-ON, NCT04844606: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease |
|
|
| Recruiting | 3 | 150 | Europe, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease | 07/30 | 07/30 | | |
NCT05905172: Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
2017-003737-29: Double-blind (neither physician nor patient knows of the actual treatment which can be with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (one of the treatment groups receives medication without active substance), phase II/III study on the efficacy and tolerability of oral budesonide suspension in comparison with placebo in children and adolescents with eosinophilic esophagitis |
|
|
| Ongoing | 2/3 | 75 | Europe, RoW | Budesonide oral suspension [0.2 mg/ml], Oral suspension | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | Active eosinophilic esophagitis and maintenance of remission in eosinophilic esophagitis, Allergic inflammatory disease of the gullet in its active and in its chronic symptom-free phase, Diseases [C] - Digestive System Diseases [C06] | | | | |
2015-000762-65: Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu |
|
|
| Ongoing | 2/3 | 7 | Europe | Cosentyx, EU/1/14/980/002; EU/1/14/980/003, Solution and suspension for suspension for injection in pre-filled syringe, Cosentyx® | Technische Universität München, School of Medicine, represented by Dean, Novartis Pharmaceuticals AG | Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising., Pyoderma gangrenosum is an autoinflammatory disease. It is difficut to treat. Treatment with a new drug against IL17 seems promising., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2016-002069-77: Follow-Up clinical trial in patients who have previously received test product RG-101 for assessment of long term safety and efficacy |
|
|
| Ongoing | 2/3 | 200 | Europe | RG-101, Solution for injection | Regulus Therapeutics Inc., Regulus Therapeutics Inc. | Hepatitis C Patients, Liver disease caused by the hepatitis C virus, Diseases [C] - Virus Diseases [C02] | | | | |
2016-000620-26: MK-3682B Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Ongoing | 2/3 | 160 | Europe | MK-3682B, MK-3682B, Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Chronic Hepatitis C Infected Patient, Chronic Hepatitis C Infected Patient, Diseases [C] - Virus Diseases [C02] | | | | |
2012-004222-25: Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's disease |
|
|
| Ongoing | 2/3 | 450 | Europe | Masitinib, AB1010, Film-coated tablet | AB Science, AB Science | Crohn's disease, Inflammatory bowel disease, Diseases [C] - Digestive System Diseases [C06] | | | | |
2020-001167-93: A clinical trial investigating efficacy and safety of emapalumab and anakinra in patients with Coronavirus disease (COVID-19) Studio clinico per valutare l'efficacia e la sicurezza di emapalumab e anakinra in pazienti con COVID-19 |
|
|
| Not yet recruiting | 2/3 | 54 | Europe | Kineret, Emapalumab, [Kineret], [Emapalumab], Solution for injection, KINERET - "100 MG/0,67 ML SOLUZIONE INIETTABILE" USO SOTTOCUTANEO SIRINGA PRERIEMPITA 7 SIRINGHE PRERIEMPITE, Gamifant | SWEDISH ORPHAN BIOVITRUM AB (PUBL), Swedish Orphan Biovitrum AB (publ) | SARS-CoV-2 infection Infezione da SARS-CoV-2, Coronavirus disease (COVID-19) Malattia da Coronavirus (COVID-19), Diseases [C] - Virus Diseases [C02] | | | | |
| Ongoing | 2/3 | 675 | Europe | Alutard SQ phleum pratense (ALK 225), Solution for injection, Alutard SQ phleum pratense (ALK 225) | Aarhus Universitet, Innovation Fund Denmark, Aarhus University Hospital, Aarhus University, ALK-Abelló, Hørsholm, ALK-Abello, Hoersholm, ALK-Abelló | Allergic rhinitis, hayfever, Body processes [G] - Immune system processes [G12] | | | | |
2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis. |
|
|
| Not yet recruiting | 2/3 | 395 | Europe, RoW | Belapectin, GR-MD-02, Solution for infusion | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Esophageal Varices in NASH Cirrhosis, Varices (enlarged veins) in oesophagus (muscular tube connecting the throat with the stomach) in patients with liver cirrhosis (scarring) due to non-alcoholic fatty liver disease with inflammation., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-004775-40: A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's Disease |
|
|
| Ongoing | 2/3 | 1265 | Europe, RoW | Etrasimod, APD334, Tablet | Arena Pharmaceuticals Inc., ARENA PHARMACEUTICALS, INC., Arena Pharmaceuticals Inc. | Crohn's Disease, Crohn's Disease a form of inflammatory bowel disease., Diseases [C] - Digestive System Diseases [C06] | | | | |
| Not yet recruiting | 2/3 | 150 | Europe | PQ Grass, Suspension for injection | Allergy Therapeutics (UK) Ltd., Allergy Therapeutics (UK) Ltd. | seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure, grass pollen allergy, Body processes [G] - Immune system processes [G12] | | | | |
2021-000069-34: The effects of peripheral opioid receptor antagonism on recurrent acute pancreatitis Effekten af perifer opioid antagonisme på recidiverende akut pankreatitis |
|
|
| Ongoing | 2/3 | 120 | Europe | Naldemedine 0.2mg Film-coated Tablet, Film-coated tablet | Mech-Sense, Aalborg University Hospital, The Novo Nordisk Foundation, Shionogi B.V. | Recurrent acute pancreatitis, Recurrent acute inflammation of the pancreas, Diseases [C] - Digestive System Diseases [C06] | | | | |
| Not yet recruiting | 2/3 | 40 | Europe | Alutard SQ phleum pratense (ALK 225), Solution for injection, Alutard SQ phleum pratense (ALK 225) | Aarhus Universitet, Innovation Fund Denmark, Aarhus University Hospital, Aarhus University, ALK-Abelló, Hørsholm, ALK-Abello, Hoersholm, ALK-Abelló | Allergic rhinitis, hayfever, Body processes [G] - Immune system processes [G12] | | | | |
NCT03519113: HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 |
|
|
| Active, not recruiting | 2/3 | 186 | RoW | GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG | Green Cross Corporation | Hepatitis B Infection | 03/22 | 09/22 | | |
| Recruiting | 2/3 | 60 | RoW | Exosome-MSC Intravenous injection, Dermama Exosome-MSC, Placebo Intravenous Injection, Placebo, COVID-19 Standard Treatment, Drugs accepted as cures for COVID-19 | Dermama Bioteknologi Laboratorium, Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia | SARS-CoV2 Infection | 06/22 | 12/22 | | |
2022-000715-31: Novel Experimental COVID Therapies Affecting Host Response (NECTAR) |
|
|
| Not yet recruiting | 2/3 | 800 | Europe | Fostamatinib, [Non applicabile], Film-coated tablet | NEAT ID, NEAT ID Foundation, National Institutes of Health (NIH) | COVID-19 viral infection Infección por el virus COVID-19, COVID-19 viral infection Infección por el virus COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
2021-006533-19: Study to assess the efficacy and safety of subcutaneous immunotherapy in patients suffering from grass pollen allergy |
|
|
| Not yet recruiting | 2/3 | 488 | Europe | CLUSTOID Phleum pratense, Suspension for injection | ROXALL Medizin GmbH, ROXALL Medizin GmbH | Patients with grass pollen-related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma, Patients with grass pollen-related hay fever (allergic rhinitis, rhino-conjunctivitis, and well-controlled mild-to-moderate or without asthma), Diseases [C] - Immune System Diseases [C20] | | | | |
2022-001610-19: Study to assess the efficacy and safety of subcutaneous immunotherapy in patients suffering from house dust mite allergy |
|
|
| Not yet recruiting | 2/3 | 832 | Europe | CLUSTOID D. pteronyssinus, Suspension for injection, CLUSTOID D. pteronyssinus | ROXALL Medizin GmbH, ROXALL Medizin GmbH | Patients with house dust mite-related allergic rhinitis/rhino-conjunctivitis and with well-controlled mild-to-moderate or without asthma, Patients with house dust mite-related allergies and mild-to-moderate asthma (allergic rhinitis/rhino-conjunctivitis and with well-controlled mild-to-moderate or without asthma), Diseases [C] - Immune System Diseases [C20] | | | | |
| Active, not recruiting | 2/3 | 180 | Europe | Placebo, MV130 | Inmunotek S.L. | Chronic Obstructive Pulmonary Disease (COPD) | 03/23 | 03/23 | | |
2021-005169-41: Clinical study to assess the efficacy and safety of sublingual allergen immunotherapy spray in patients suffering from house dust mite allergy |
|
|
| Not yet recruiting | 2/3 | 996 | Europe | SULGEN® Spray D. pteronyssinus, Sublingual spray, solution | ROXALL Medizin GmbH, ROXALL Medizin GmbH | Patients with house dust mites related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma, Inflammation of the nose and/or eyes and asthma caused by house dust mites, Diseases [C] - Immune System Diseases [C20] | | | | |
2022-001587-97: Study to assess the efficacy and safety of subcutaneous immunotherapy in patients suffering from birch pollen-related allergy |
|
|
| Not yet recruiting | 2/3 | 560 | Europe | CLUSTOID Birke, Suspension for injection | ROXALL Medizin GmbH, ROXALL Medizin GmbH | Patients with birch pollen-related allergic rhinitis/rhinoconjunctivitis and with well-controlled mild-to-moderate or without asthma, Patients with birch pollen-related hay fever and mild-to-moderate asthma or without asthma, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 2/3 | 150 | Europe | AMT-101, Gastro-resistant tablet | Applied Molecular Transport Inc., Applied Molecular Transport Inc. | Pouchitis, Inflammation of the ileal pouch - an artificial rectum surgically created out of ileal gut tissue in patients who have undergone a colectomy., Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C |
|
|
| Recruiting | 2/3 | 520 | RoW | HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo | Sunshine Lake Pharma Co., Ltd. | Chronic HCV Infection | 04/23 | 04/23 | | |
| Active, not recruiting | 2/3 | 30 | US | Hyperbaric Oxygen Therapy | TruDiagnostic | Aging | 04/23 | 07/23 | | |
| Recruiting | 2/3 | 34 | Europe | Dapagliflozin 10mg Tab, Placebo | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, AstraZeneca | Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension | 09/24 | 09/24 | | |
| Active, not recruiting | 2/3 | 68 | Europe, Canada, Japan, US, RoW | VAY736, Placebo | Novartis Pharmaceuticals | Autoimmune Hepatitis | 12/23 | 12/25 | | |
NCT05194007: Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease |
|
|
| Recruiting | 2/3 | 100 | RoW | Frondanol, Placebo | Mohammed Bin Rashid University of Medicine and Health Sciences, Mediclinic Middle East, Rashid Hospital, Dubai Health Authority | Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Crohn Colitis | 06/24 | 01/25 | | |
NCT04787471: Corneal Crosslinking for Treatment of Corneal Neovascularization |
|
|
| Recruiting | 2/3 | 62 | US | 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1% | Price Vision Group, Cornea Research Foundation of America | Corneal Neovascularization | 04/25 | 07/25 | | |
| Recruiting | 2/3 | 1250 | Europe, RoW | RESCAP®, placebo | Alloksys Life Sciences B.V., Aix Scientifics | Systemic Inflammation, Cardiopulmonary-bypass | 09/25 | 03/26 | | |
NCT05457946: Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series |
|
|
| Not yet recruiting | 2/3 | 1438 | NA | LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) | LG Chem | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B Infection | 09/25 | 09/25 | | |
MM09-SLIM, NCT05641272: Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract |
|
|
| Not yet recruiting | 2/3 | 90 | RoW | 3,000 MM09, 9,000 MM09, Placebo sublingual | Inmunotek S.L., LAT Research, Xolomon Tree S.L. | Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite | 06/26 | 12/26 | | |
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2/3 | 700 | US | GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin | Gritstone bio, Inc. | Colorectal Neoplasms | 03/27 | 03/27 | | |
